Welcome to the conference call hosted by Daré to provide Fiscal Year End 2017 Financial Results and General Business Update. This call is being recorded. My name is Kathleen and I’ll be your operator today. With us today are Sabrina Martucci Johnson, Daré’s President and Chief Executive Officer and Lisa Walters-Hoffert, Daré’s Chief Financial Officer. Miss Johnson please proceed.

Thank you. And welcome to our fiscal year end 2017 financial results and business update call for Daré Bioscience. It’s a pleasure to have the opportunity to talk about our results to date and our company highlights, as well as our 2018 milestones. Today’s discussion will include forward-looking statements. And as such I would like to start with a comment about those forward-looking statements. I would like to remind you that we will be making statements during this call include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. Factors that might cause such difference include those set forth from time to time in our SEC filings, including our report on Form 10-K for the year ended December 31, 2017. Daré is a bio pharmaceutical company squarely focused on improving the life and wellbeing of women. In fact we’re a pure play women health company identifying and addressing gaps in women's reproductive and sexual health. Many of you know that women’s health encompass significant growing global market. Contraception alone is expected to grow to $32 billion, women's health to $22 billion and male and female sexual dysfunction to $8 billion. Many differentiated products in these markets segments have each delivered sales and revenues ranging from $500 million to $1 billion in the U.S. 2017 was a year of transformative growth for Daré as we established…

Thank you, Sabrina. And thanks to all of you participating on this call. So I would like to take a brief moment and summarize Daré’s highlights over the last nine months, as well as our anticipated 2018 milestones, some of which Sabrina has touched on. On July 19, 2017 Daré Bioscience Operations and Cerulean Pharma completed a stock purchase transaction and the company's name was subsequently changed to Daré Bioscience Inc. In February of 2018 Daré entered into a worldwide licensing development agreement for a clinical Phase stage 2b asset, Topical Sildenafil, for the treatment of female sexual arousal disorder. As Sabrina mentioned, we intend to communicate with the U.S. Food and Drug Administration or the FDA in mid-2018 regarding to Phase 2B topical study – excuse me, study of Topical Sildenafil. Pending the outcome of these interactions we anticipate commencing a Phase 2B study of Topical Sildenafil in the fourth quarter of 2018. In March of 2018 we entered into a worldwide development and option agreement for novel injectable formulations of etonogestrel seeking to provide contraceptive protection for periods ranging from six and 12 months. And the finally, we expect to commence the enrollment of our Ovaprene postcoital test clinical trial in the second quarter of 2018, which is actually this quarter. In terms of the full year 2017 financial summary, let me walk you through that. As of December 31, 2017, we had approximately $7.56 million in cash. We believe this existing cash balances plus approximately $10.4 million of net proceeds received from the sale of equity securities in February 2018 will be sufficient for Daré to commence and complete a postcoital test trial of Ovaprene and to advance Topical Sildenafil into Phase 2b clinical development program. Our general and administrative expenses for the full year ended December…

Thank you Lisa. We’ll now turn it over to the operator who will open the lines for some Q&A.

[Operator Instructions] And our first question comes from Yasmeen Rahimi with ROTH Capital Partners. Your line is now open.

Great thank you. Thank you so much for taking my question. A number of questions on the upcoming communication with the FDA. So maybe some insight on as you're going for an – with the FDA, what sort of a trial design are you proposing? What are the key discussion points? And what could be a best-case scenario and the worst-case scenario coming out of those communications?

Great. Yasmeen thank you for the question. This is Sabrina. In October of 2016, the FDA issued a draft guidance document that covers the indication for female sexual arousal disorder. As I mentioned in my comments, there's nothing currently approved for the indication, which is why we're so interested in pursuing Topical Sildenafil for it. What that does mean is that we have an opportunity to help lay that path with the FDA around that trial design, as you outlined. And so in terms of our main objectives for that communication, it's really around framing that IIb program, and importantly also, the Phase III program that will follow that and making sure that we're aligned on expectations around really primarily a few factors. One would be the inclusion criteria, female sexual arousal disorder, making sure there is agreement on how we would intend to screen the subjects and the instruments that we would propose utilizing for that, that is in use in other studies and how we're going to use those. Second would be making sure there's alignment on the actual questionnaire. This is – while its blood flow to the region that is what allows that arousal response in a clinical study setting and in at-home trial, we would need to rely on women reporting about their experience. And so second is making sure there's alignment with the FDA based on the very broad guidance they provided in their document on the specifics around the end points that we would be selecting, the frequency of asking those questions, the specific questions selected about arousal disorder that we would be asking. And then third, is really around the duration of the study. So the guidance document does speak to, for Phase 3 program, needing to look at subjects for six months. We want to understand if that expectation is the same for a 2b program and also related to that sort of duration of use is also number of arms to include in the subject – in the study for each subject. Is it placebo and one dose? Or will it be multiple doses that need to be evaluated? So in terms of best case and worst case, they're all designed to maybe be very comfortable with. Obviously, the larger the study, the number of arms and the longer duration does have an impact on the time frame for reporting those results and, of course, the size of the study.

Great. Thank you so much.

[Operator Instructions] At this time, I'm showing no further questions. I would like to turn the call back over to Ms. Johnson for closing remarks.

Well, thank you. I want to thank everyone for taking the time this afternoon. We always appreciate an opportunity to share the story and provide the updates, and we absolutely look forward to keeping you updated on our progress over the next several months. Thank you.

Ladies and gentlemen, thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.